| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_338122610c66aec3edaa563d6ecc7b71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fec4337665eedc2ce05fc3a146b0b0ad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate |
2018-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e73c1436c9da3d456039a665453bbf90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1699bf1cbe67734e3fb8a5038ad89d96 |
| publicationDate |
2019-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109503715-A |
| titleOfInvention |
Fusion protein of IL-4R and its application |
| abstract |
The present invention provides immune effector cells expressing a fusion protein comprising a cytokine binding extracellular domain and a signal transduction intracellular domain, wherein the extracellular domain is an IL4 receptor extracellular domain, The intracellular domain is the IL-21 receptor intracellular domain. The immune effector cells have significant anti-tumor ability in the tumor microenvironment of solid tumors, so that they are not only effective against solid tumor cells in vitro, but also have excellent killing effect on solid tumor cells in vivo. The present invention also provides pharmaceutical compositions comprising the immune effector cells and their uses. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111875694-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111875694-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114867847-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021249555-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022268162-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022028623-A1 |
| priorityDate |
2017-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |